An observational study in Hearing Loss, Sensorineural, sponsored by Institut Pasteur. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Institut Pasteur · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies in Hearing Loss, Sensorineural with a site in France — 14 open to participants now, 16 under way, none of them phase 3. Hearing Loss, Sensorineural · France.
Among the 38 studies in Hearing Loss, Sensorineural with a site in France, this one is the 5th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2019, is one of 10 observational ones, reaches primary completion later than 11 of the 15 other live ones, and was the 8th registered.
346 studies on the registry are indexed under Hearing Loss, Sensorineural; 101 are open to participants now.
Browse Hearing Loss, Sensorineural studies →14 of the 38 studies in Hearing Loss, Sensorineural with a site in France are open now. Recruiting first, the newest first:
University Hospital, Strasbourg, France · Sites in France
Ages 0 yrs–1 mo
Advanced Bionics AG · Sites in France
Ages 18+
MED-EL Elektromedizinische Geräte GesmbH · Sites in France
Ages 18+
MED-EL Elektromedizinische Geräte GesmbH · Sites in France
Ages 18+
MED-EL Elektromedizinische Geräte GesmbH · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 70 Hearing Loss, Sensorineural studies recruiting now, 39 (56%) set no upper age limit and 19 (27%) stop at 75 or younger; 26 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2019.
This study's planned enrollment of 100 is above the median of 70 across 86 observational studies indexed under Hearing Loss, Sensorineural.
Median enrollment 24 across the 28 interventional studies, 76 across the 10 observational. Of the 20 that completed or were terminated, 1 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 38 have an industry lead sponsor. The 10 most frequent:
Institut Pasteur is the lead sponsor of 99 studies on the registry; 41 are open to participants now.
Institut Pasteur has 3 studies filed under Hearing Loss, Sensorineural — fewer than ten, so there is no comparison to draw.
8 of the studies in Hearing Loss, Sensorineural with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06894303Advanced Bionics AGEvaluation of Remote Programming of Cochlear Implants in Routine Cochlear Implant Follow-up | 2026-12 |
| NCT05898659MED-EL Elektromedizinische Geräte GesmbHComparison in New Cochlear Implanted Subjects of a Tonotopy-based Bimodal Fitting With or Without Synchronization | 2026-12-15 |
| NCT06268340Advanced Bionics AGHearing and Structure Preservation Via ECochG | 2026-12-31 |
| NCT05955469MED-EL Elektromedizinische Geräte GesmbHComparison in New Cochlear Implanted Subjects of a Tonotopy-based Bimodal Fitting and a Conventional Fitting | 2027-01-01 |
| NCT06737185MED-EL Elektromedizinische Geräte GesmbHComparison of Speech Understanding Between Tonotopy-based Fitting and Setting Based on Evolutionary Algorithms | 2027-01-15 |
Add all 8 to your calendar (.ics) → With an account.
Among the 38 studies in Hearing Loss, Sensorineural with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Gene therapy is a promising strategy to treat hearing loss and vestibular disorders, and Associated adenovirus (AAV) is shown as a good viral vector for inner ear therapy in animal models.
This study aims to study in vitro viral transduction of AAV in human inner ear cells, collected during non-conservative surgeries for vestibular schwannoma.
Patients undergoing surgical resection of vestibular schwannoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collection of inner ear cells during a non-conservative surgical approach (translabyrinthine or transotic).
Other: Peroperative collect of inner ear cells
After obtaining an informed consent during the preoperative medical visit, and if a non-conservative approach (translabyrinthine or transotic) is decided, the collect of inner ear cells will be performed during surgical approach. The sample will be collect in a sterile tube, and carried to the laboratory were it will be placed bon cell culture.
AAV transduction in inner ear cells
The transduction will be measured with immunostaining techniques
Time frame: 10 days
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2019 (actual). Primary completion is estimated for Feb 2027, 95 months after the start.
Of 42 observational studies under Hearing Loss, Sensorineural, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 13. This study's planned 95 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.